CELLULAR GENOME POSITIONING SYSTEM (CGPS)
LIVE

Serial Number

79071885

Owner

CELLECTIS

Filing Date

Apr 22, 2009

Add to watchlist:

No watchlists yet
View on USPTO

CELLULAR GENOME POSITIONING SYSTEM (CGPS) Trademark

Serial Number: 79071885 • Registration: 3847971

CELLULAR GENOME POSITIONING SYSTEM (CGPS) is a trademark filed by CELLECTIS on April 22, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

CELLECTIS (10 trademarks)

102 avenue Gaston Roussel

Entity Type: 99

Trademark Details

Filing Date

April 22, 2009

Registration Date

September 14, 2010

Published for Opposition

June 29, 2010

Cancellation Date

April 23, 2019

Goods & Services

Scientific apparatus and instruments used in the implementation of biochemical analysis and molecular biology techniques, namely, automated biochemical analyzer, automated protein production and protein purification devices, biochemical, biological automated assay devices, nucleic acid break analyzer, devices for protein-nucleic acid interaction analysis; scientific apparatus and instruments for the mapping of all molecules' biological activities; data processing apparatus; multimedia products, namely, blank magnetic, blank optical, blank image and blank sound recording media; software for recording scientific and medical data on an on-line computer database in the field of pharmaceuticals and biotechnology, for simulation and design of biological and chemical products; apparatus and instruments for non-medical diagnosis, namely, computer hardware, microscopes, spectrometers

Pharmaceutical, veterinary and sanitary preparations, namely, dietetic beverages, foodstuffs and substances for medical purposes, nutritional additives for medical purposes cultures and preparations of microorganisms for medical, pharmaceutical and veterinary purposes, bacteriological preparations for medical, pharmaceutical and veterinary purposes, medicines for veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, medicines for human purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, biological preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical and biochemical preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical and biochemical preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical-pharmaceutical preparations for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites; diagnostic preparations for medical purposes

Chemical, biochemical, biotechnological and bacteriological products used in industry, science, agriculture, horticulture, namely, chemicals used for industrial purposes, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases; chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, chemicals used for research purposes, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological preparations for scientific purposes, namely, chemicals used for scientific purposes, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; diagnostic preparations for scientific purposes; proteins being raw materials; reagents for the preparation or transport of biological molecules for scientific purposes

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Nov 8, 2019 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 8, 2019 DETH
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 2, 2019 ADCH
TOTAL INVALIDATION PROCESSED BY THE IB
Jan 26, 2018 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Dec 28, 2017 XXSS
GENERIC MADRID TRANSACTION CREATED
Dec 28, 2017 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 21, 2017 INTR
CANCELLED SECTION 71
Apr 21, 2017 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Mar 27, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 18, 2013 FINO
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 28, 2013 TCCA
FINAL DISPOSITION NOTICE SENT TO IB
Dec 15, 2010 FICS
FINAL DISPOSITION PROCESSED
Dec 15, 2010 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 14, 2010 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 14, 2010 R.PR
PUBLISHED FOR OPPOSITION
Jun 29, 2010 PUBO
NOTICE OF PUBLICATION
Jun 9, 2010 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 25, 2010 PREV
EXAMINERS AMENDMENT MAILED
May 24, 2010 CNEA
APPROVED FOR PUB - PRINCIPAL REGISTER
May 24, 2010 CNSA
EXAMINER'S AMENDMENT ENTERED
May 24, 2010 XAEC
EXAMINERS AMENDMENT -WRITTEN
May 24, 2010 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
May 24, 2010 ZZZX
ASSIGNED TO LIE
May 12, 2010 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 3, 2010 CNSA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 7, 2010 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 7, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 7, 2010 TROA
REFUSAL PROCESSED BY IB
Oct 30, 2009 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 7, 2009 RFCS
REFUSAL PROCESSED BY MPU
Oct 7, 2009 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 7, 2009 RFCR
NON-FINAL ACTION WRITTEN
Oct 6, 2009 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 22, 2009 MAFR
ASSIGNED TO EXAMINER
Sep 18, 2009 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 18, 2009 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 17, 2009 REPR